How cells respond to stress from damaged ribosomes
Molecular mechanisms of ZAK- and GCN2-mediated signaling in response to ribotoxic stress
This study is looking at how cells handle stress when their protein-making machines get damaged, especially from things like UV light, and it focuses on two important proteins that help the cells respond, which could help us understand how to keep cells healthy or how they might die.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10900612 on NIH RePORTER |
What this research studies
This research investigates the cellular mechanisms that allow cells to detect and respond to stress caused by damaged ribosomes, particularly in the context of exposure to ultraviolet radiation and reactive oxygen species. The study focuses on two key proteins, ZAK and GCN2, which are activated when ribosomes stall due to RNA damage. By using advanced techniques like phosphoproteomics, the researchers aim to create a detailed map of the signaling events that occur in response to this stress, ultimately helping to understand how these processes influence cell survival or death.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that involve cellular stress responses, such as cancer or other diseases characterized by ribosomal dysfunction.
Not a fit: Patients with conditions unrelated to ribosomal stress or those who do not exhibit cellular response issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for protecting cells from stress-related damage, potentially improving treatments for conditions like cancer.
How similar studies have performed: Previous research has shown promising results in understanding cellular stress responses, indicating that this approach has potential for significant advancements.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Sinha, Niladri K — Johns Hopkins University
- Study coordinator: Sinha, Niladri K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.